Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
about
HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathwayEvacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressureEffects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefitNevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1CETP Inhibition: Past Failures and Future HopesDysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and LipidomicsCardioprotective functions of HDLsCrystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid moleculesHigh-Density Lipoprotein Processing and Premature Cardiovascular DiseaseEvaluating and treating cardiometabolic risk factors: a case discussionAtherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsDescription of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actionHuman apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changesATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteinsCholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular riskTherapy insight: heart disease and the insulin-resistant patient.The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Nuclear receptors as drug targets for metabolic disease.Screening the human serum proteome for genotype-phenotype associations: an analysis of the IL6 -174G>C polymorphism.Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Study of Cholesteryl Ester Transfer Protein (CETP) I405v Genotype and Its Association with Lipid Fractions in Myocardial Infarction Patients: A Case Control Study.Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation.Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patientsAnti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a reviewCholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Aldosterone production in human adrenocortical cells is stimulated by high-density lipoprotein 2 (HDL2) through increased expression of aldosterone synthase (CYP11B2)Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort StudiesCETP genotype and changes in lipid levels in response to weight-loss diet intervention in the POUNDS LOST and DIRECT randomized trials.eNOS activation by HDL is impaired in genetic CETP deficiency.Molecular regulation of HDL metabolism and function: implications for novel therapies.New insights into the mechanism of low high-density lipoprotein cholesterol in obesityPathophysiology of dyslipidaemia in the metabolic syndrome.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Endothelial FAK as a therapeutic target in disease.
P2860
Q24323992-E6677160-331A-468F-B856-D05497C9CB09Q24624286-46D82C13-C924-42ED-A48F-A467CDFCDF7FQ24650533-1664D7CE-E0A4-4C1D-8C50-2C8E60D4D40CQ24802369-D014A185-A305-4EBB-B953-58B756C14580Q26753158-58E04E02-31A4-40CE-839C-63CDC6CC8577Q26774903-F1C6D691-A82B-4F29-AAF1-ADBF795A0C3CQ27000421-68B444B3-647E-4EA5-AB2E-0D7EE204D69BQ27643587-96A5F68A-C6BA-43AA-A73C-982732B9AB9EQ28085143-2104CE4F-AFD2-4831-95E7-02FB9E2BC37CQ28196750-11964969-80DF-48CB-B34B-8B4DD22E5CC3Q28200554-F37FFA5F-593B-4FB0-AB21-7CF8169BA41DQ28285064-29480800-D7D9-484D-8903-89384FFF06ABQ28570515-24F6569B-5248-4D48-BA7A-7A53BB184B69Q28594013-C574A815-2387-4278-870E-FBC8326A09EDQ28731522-8AB3288F-AE43-48A4-A693-969CB40CA8FFQ30351748-FD489B81-3B37-4C5A-B1E5-AF86914FA7EFQ30380628-B17034D1-2BE2-43FC-9304-5DA692FAF84EQ30430126-7D7D2440-8AB0-4943-B701-205AF26AF167Q33274516-1263986E-6A4F-46B2-8B63-A4A47019FCA5Q33612543-D45E53A2-73DB-4D3A-9C95-3C0EBDB71C33Q33639433-49A8C403-B9A8-42AB-8C92-02B8421C431BQ33717612-43E82147-335A-4F3D-9E2E-7A2515E01774Q33924365-909705A4-BBD3-4051-968D-4E3AE853E78FQ33993233-DD36E3B5-D19F-4471-9C42-D21230406293Q34030331-9724D52E-DDF6-4898-85E3-8E2CC52B1889Q34075414-A608D91B-8157-4BDA-B4CE-BD9E8996F148Q34236254-2E82D730-F5E7-4D57-A2BC-3136C8A75851Q34238630-FA608AFD-345B-439C-B978-9F03499A009EQ34243501-82DED5A7-BDD2-4D45-9DDF-80D004B52E4CQ34441411-D8BE59D9-634C-40B8-A842-3C68C53016F2Q34578466-DEB0EE13-A7A1-4759-BB44-9B30A773A1B7Q34628218-9C3D26BF-6BB3-43D9-94DF-8857D7850D56Q35032753-DE430590-9FDE-42CE-9713-6A20531510B9Q35120965-A4000090-36FD-4285-983D-A2A391F7B799Q35168995-ADBFB643-4B74-4FA8-84B8-D284CCB03543Q35191066-8CDE4206-0032-40C9-B294-CB3FD38E4A18Q35521069-4834F6B0-30C0-493C-9D3E-5F6115E98EDEQ35522107-DCE937F8-E570-4ABC-B4B8-23CE953AF885Q35590298-E3408EB6-274B-4309-9FE3-EADAABE0A0ABQ35597214-DA22733A-0AC1-4876-A121-66A4BE7D1B10
P2860
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@ast
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@en
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@nl
type
label
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@ast
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@en
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@nl
prefLabel
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@ast
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@en
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@nl
P2093
P3181
P356
P1476
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
@en
P2093
Andres G Digenio
Daniel J Rader
Ernst J Schaefer
James P Mancuso
LeAnne T Bloedon
Margaret E Brousseau
Megan L Wolfe
Ronald W Clark
P304
P3181
P356
10.1056/NEJMOA031766
P407
P577
2004-04-08T00:00:00Z